CD28 and colitis: It was hypothesized that a D2R antagonist would inhibit the therapeutic effect of TA on DSS-induced colitis and might even exacerbate the colitis due to its ability to reverse TA-mediated modulation of cytokine secretion by LPS- and CD3/CD28-stimulated splenocytes (Fig. 7).